araag2/HINT huggingface dataset:
Clinical trial NCT00723606 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: intramuscular ziprasidone mesylate, intramuscular haloperidol
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female Chinese subjects aged 18-65 years (including 65) at screening.

          -  Subjects meeting the ICD-10 (Classification of Mental and Behavioral Disorders)
             criteria for schizophrenia (F20.X).

          -  Subjects who are in acute phase of schizophrenia and are appropriate to receive
             intramuscular medication for at least 3 days

        Exclusion Criteria:

          -  History of clinically significant physical illness especially myocardial infarction,
             non compensatory heart failure etc.

          -  Subjects receiving an investigational agent in the previous 3 months prior to
             screening.

          -  Use of antipsychotic agents within 12 hours or parenteral benzodiazepines within 4
             hours prior to randomization and during the study.
Clinical trial NCT00145496 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have a documented current diagnosis of schizophrenia of paranoid, disorganized,
             catatonic, residual, or undifferentiated subtype with persistent negative symptoms.

          -  No increase in level of psychiatric care during the past few months due to worsening
             of symptoms of schizophrenia.

          -  Caregiver required.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant medical condition.

          -  Have any other psychiatric disorder other than schizophrenia as a primary diagnosis
             including depression.
Clinical trial NCT00676650 (phase 3, status: terminated)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: prednisone, sunitinib, placebo, prednisone
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    study a6181120 was prematurely discontinued due to futility on 27 september 2010. no new or
    unexpected safety issues were identified.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.

          -  Progressive, metastatic castration-resistant prostate cancer after failure of
             docetaxel chemotherapy (resistant or intolerant).

          -  Progressive disease based on PSA progression, RECIST, or positive bone scan.

          -  ECOG 0 or 1.

        Exclusion Criteria:

          -  Prior treatment with sunitinib and/or more than 1 prior chemotherapy regimen in the
             metastatic disease setting.

          -  Chemotherapy within 3 weeks.

          -  Impending complications from bone metastases.

          -  Ongoing urinary obstruction.

          -  Cardiac dysfunction, QTc >470 msec.

          -  CNS involvement.
Clinical trial NCT01035229 (phase 3, status: completed)
Conditions: carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: everolimus, everolimus placebo
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced liver cancer

          -  Prior systemic treatment with sorafenib for advanced HCC and for whom their disease
             progressed during or after sorafenib treatment, or were intolerant to sorafenib
             treatment. Specifically, this can be defined as:

               -  Documented radiological confirmation (radiology scans or report) of disease
                  progression during or after sorafenib treatment

               -  Intolerance to sorafenib (at any dose and/or duration) is defined as documented
                  sorafenib-related grade 3 or 4 adverse events that led to sorafenib
                  discontinuation.

        NOTE:

          -  Sorafenib must be the last antineoplastic treatment before randomization

          -  Prior local and/or hormonal therapy (e.g., tamoxifen) before sorafenib is allowed

          -  One systemic chemotherapy regimen for advanced HCC is allowed before sorafenib
             treatment

               -  ECOG performance status of ≤ 2

               -  Child-Pugh A

        Exclusion Criteria:

          -  Active bleeding during the last 28 days

          -  Prior therapy with mTOR inhibitors

          -  Prior liver or other organ transplantation which mandates systemic immunosuppression

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01582230 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with confirmed diagnosis of Type2 diabetes mellitus (T2DM) by standard
             criteria

          -  C-peptide >0.6 ng/ml (>0.20 nmol/L).

          -  HbA1c ≥7.5 to ≤11% at Visit 1

          -  Treatment with stable, once or twice daily doses (maximum dose of < 1 unit/kg/day) of
             basal (long-acting, intermediate-acting) insulin alone or pre-mixed insulin for at
             least 12 weeks prior to Visit 1. Stable is defined as ±10% of the Visit 1 dose during
             the previous 12 weeks

          -  Patients receiving metformin must be on a stable dose of metformin (at least 1500 mg
             daily or a maximally tolerated dose) for at least 12 weeks prior to Visit 1

          -  Body Mass Index (BMI) ≥20 to ≤40 kg/m2 at Visit

        Exclusion Criteria:

        Patients fulfilling any of the following criteria are not eligible for participation in the
        study

          -  Fasting plasma glucose (FPG) ≥240 mg/dl (13.3 mmol/L) at Visit 1

          -  Pregnant or lactating women

          -  Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state
             (coma) within the past 6 months

          -  Current diagnosis of congestive heart failure (NYHA III or IV).

          -  Myocardial infarction (MI) within the past 6 months

          -  Liver disease such as cirrhosis or chronic active hepatitis

        Other protocol defined inclusion/excusion criteria may apply
Clinical trial NCT00343460 (phase 3, status: completed)
Conditions: nausea and vomiting, unspecified adult solid tumor, protocol specific
ICD codes: R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: apf530, dexamethasone, palonosetron hydrochloride
SMILES: CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed malignant disease

               -  No head and neck cancer or upper gastrointestinal cancer

          -  Scheduled to receive a single day of moderately or highly emetogenic chemotherapy
             regimen (for ≤ 4 courses)

               -  Chemotherapy administration ≤ 4 hours

               -  Duration of each course ≤ 28 days

               -  Causing nausea and vomiting in 30-100% of patients if untreated according to
                  Hesketh algorithm

          -  Must be able to receive standardized doses of dexamethasone for the prevention of
             emesis during study treatment

          -  No greater than mild nausea or any vomiting within 24 hours before beginning study
             treatment

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known allergy or hypersensitivity to other selective 5-HT3 receptor antagonists or
             local anesthetics

          -  QTc interval ≤ 500 ms

          -  No cardiac abnormality predisposing the patient to arrhythmia

          -  No psychological problem that, in the opinion of the investigator, is severe enough to
             preclude study participation

          -  No recent history (i.e., ≤ 1 year) of alcohol or drug abuse

          -  No concurrent condition that, in the opinion of the investigator, could affect
             assessment of study medication or interfere with the nausea/vomiting response (e.g.,
             severe renal or hepatic impairment)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No radiotherapy 7 days prior to, during, and 5 days after completion of study
             treatment

          -  More than 7 days since prior chemotherapy

          -  More than 7 days since prior and no concurrent prohibited medications (e.g., CYP3A4
             inhibitors or other antiemetic medications)

          -  More than 7 days since prior antinausea medications

          -  More than 30 days since prior treatment on an investigational trial

          -  No other concurrent corticosteroids or dexamethasone at a different dose than study
             treatment

          -  No concurrent use of APF530, palonosetron hydrochloride, or aprepitant as rescue
             medications
Clinical trial NCT00560417 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin lispro protamine suspension, insulin glargine
SMILES: OC(=O)[C@@H]1CCCN1, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have type 2 diabetes

          -  Must be at least 18 years of age and less than 75 years of age

          -  Must be taking exenatide 10 micrograms twice a day (BID) for at least 3 months

          -  Must be taking one of the following oral diabetes medication regimens for at least 3
             months: (1) metformin (2) metformin + sulfonylurea (3) metformin + thiazolidinedione
             (TZD). Doses must be at or above the following: Metformin--1500 mg/day,
             Sulfonylurea--1/2 the maximum daily dose according to the product label, TZD--30
             mg/day pioglitazone

          -  Must have a hemoglobin A1C greater than or equal to 7.0% and less than or equal to
             10.0%

        Exclusion Criteria:

          -  Must not have used insulin on a regular basis during the past 2 years

          -  Must not have taken any glucose-lowering medications not included in the inclusion
             criteria in the past 3 months

          -  Must not have had more than one episode of severe hypoglycemia in the past 6 months

          -  Must not have clinically significant hematologic, oncologic, renal, cardiac, hepatic,
             or gastrointestinal disease

          -  Must not be pregnant or intend to get pregnant during the course of the study
Clinical trial NCT00253747 (phase 3, status: completed)
Conditions: adhd, smoking
ICD codes: O99.334, O99.335, Y93.G2, O99.330, O99.331, O99.332, O99.333
Drugs: osmotic-release methylphenidate, placebo
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of ADHD2

          -  Smoked cigarettes for at least 3 months

          -  Currently smoking > 10 cigarettes/day

          -  Have an interest in quitting

          -  Negative urine screen for cocaine, methamphetamine, opiates, benzodiazepines, and
             marijuana

        Exclusion Criteria:

          -  Have a clinical diagnosis for current abuse or dependence for any psychoactive
             substance other than nicotine, depression, or anxiety; or a life-time clinical
             diagnosis of psychosis or bipolar disorder

          -  Allergic to OROS-MPH

          -  Pregnant or breastfeeding

          -  Abnormal electrocardiogram (ECG)

          -  Taking a Monoamine Oxidase (MAO) Inhibitor

          -  Taking any medication used for treating either ADHD or smoking

          -  Use of tobacco products other than cigarettes in the past week

          -  Blood pressure readings greater than 135/85 and/or a heart rate more than 90 beats per
             minute on three consecutive clinic visits
Clinical trial NCT01309737 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cp-690,550, cp-690,550, placebo/cp-690,550, placebo/cp-690,550
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older with diagnosis for at least 12 months of moderate to severe plaque
             psoriasis covering at least 10% of body surface area

          -  A Psoriasis Area and Severity Index (PASI) score of 12 or greater

          -  Are considered to be candidates for systemic or light therapy

          -  Have no evidence of active or latent tuberculosis

        Exclusion Criteria:

          -  Non-plaque or drug-induced forms of psoriasis

          -  Cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot
             discontinue phototherapy (PUVA or UVB)

          -  Any uncontrolled significant medical condition
Clinical trial NCT00736853 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: tramadol hydrochloride plus acetaminophen (open-label), tramadol hydrochloride plus acetaminophen (double-blind), placebo (double-blind)
SMILES: COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C, COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with sustention of chronic pain associated with OA or LBP for at least 3
             months

          -  Participants whose pain cannot be controlled sufficiently with at least 14-day
             continuous treatment with identical oral NSAIDs at a usual maximum dose during 3
             months prior to this study

          -  Outpatients

          -  Ambulatory participants without need for any supportive device or assistance during
             daily life

        Exclusion Criteria:

          -  Participants with conditions for which opioids are contraindicated

          -  Participants with conditions for which acetaminophen is contraindicated

          -  Participants with history of convulsion or the possibility of convulsive seizure

          -  Participants with concurrent, previous, or possible alcohol dependence, drug
             dependence, or narcotic addiction

          -  Pregnant participants or those who may be pregnant, lactating mothers, and
             participants who wish pregnancy during the study period
Clinical trial NCT00194116 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: divalproex sodium er, placebo
SMILES: CCCC(CCC)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must give consent to participate in the study and sign and date the IRB
             approved written informed consent form prior to the initiation of any study procedures

          -  Subject must be between the ages of 18 and 70

          -  Subject must have a diagnosis of bipolar I or II.

          -  Subject must be currently depressed as confirmed by the Mini-International
             Neuropsychiatric Interview (MINI)

          -  Subject must have a baseline Montgomery-Asberg Depression Scale (MADRS) score of >19
             and Young Mania Rating Scale (YMRS) score of <12

          -  Women of childbearing potential must be nonpregnant/nonlactating and using adequate
             contraception if sexually active

          -  Subject must not be using any concomitant psychotropic medications during the acute
             phase except prn benzodiazepines

        Exclusion Criteria:

          -  Subjects lacks the capacity to provide informed consent

          -  Subject has currently or previously used divalproex or Dvpx-ER

          -  Subject is a serious suicide risk or has medically unstable conditions as judged by
             the investigators

          -  Subject has any alcohol, cocaine, or cannabis dependence within 3 months of study
             entry

          -  Subject has any cocaine, hallucinogens, opiates, crystal methamphetamine, or MMDA
             abuse within 3 months of study entry
Clinical trial NCT00568178 (phase 3, status: completed)
Conditions: proteinuria
ICD codes: R80.0, R80.8, R80.9, R80.1, R80.2, R80.3, O12.10
Drugs: losartan potassium, comparator: amlodipine besylate, enalapril maleate
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant is 1 to 17 years of age

          -  Able to provide a first-morning urine sample each day during the study

          -  Documented history of proteinuria associated with chronic kidney disease of any origin

          -  Signed consent of parent and/or legal guardian

        Exclusion Criteria:

          -  Pregnant and/or nursing

          -  Requires more than 2 medications to control high blood pressure

          -  Has undergone major organ transplantation (e.g. heart, kidney, liver)

          -  Known sensitivity to losartan or other similar drugs, or any history of angioneurotic
             edema

          -  Known sensitivity to amlodipine or other calcium channel blocker

          -  Requires cyclosporine to treat renal disease (kidney disease)
Clinical trial NCT00409773 (phase 3, status: completed)
Conditions: hypercholesterolemia, metabolic syndrome
ICD codes: E78.01, E78.00, Z83.42, E88.81
Drugs: ezetimibe (+) simvastatin, comparator: atorvastatin calcium, comparator: placebo (unspecified)
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia at
             high risk for coronary heart disease (CHD) with LDL-C above 70 mg/dL or 100 mg/dL
             depending on their CHD risk category

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, pose a risk to the patient or
             interfere with participating in the study

          -  Patient is likely to be greater than 20% noncompliant in taking study medications

          -  Patients with chronic medical conditions

          -  Patients with unstable doses of medications

          -  Pregnant or lactating women, women intending to become pregnant

          -  Patient is currently receiving prescription therapy with statins or other
             lipid-altering medications

          -  Patient with Type 1 or Type 2 diabetes mellitus that is poorly controlled, newly
             diagnosed, or is taking new or recently adjusted antidiabetic pharmacotherapy (with
             the exception of +/- 10 units of insulin)
Clinical trial NCT00265642 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: irbesartan, placebo
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  age between 18 and 75 years

          -  liver biopsy performed (less 18 month before inclusion), fibrosis score F2,F3 or F3+
             in Metavir classification,

          -  patients without antiviral therapy

          -  contraindication to anti viral treatment

          -  non responders or relapsers patients to past antiviral treatment

        Exclusion Criteria:

          -  hepatocellular carcinoma

          -  HIV

          -  alcool abuser

          -  cirrhosis

          -  anti-fibrotic treatment

          -  pregnancy or breast feeding
Clinical trial NCT00451295 (phase 3, status: terminated)
Conditions: chronic kidney disease, dialysis, hyperphosphatemia
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: mci-196(colestilan(inn), colestimide(jan), cholebine®), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was stopped because of insufficient enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, 18 to 80 years of age.

          2. Stable phosphate control using Calcium-based phosphate-binding medication only.

          3. The subject is undergoing regular dialysis treatment.

          4. On a stabilised phosphorus diet.

          5. If female and of child-bearing potential, has a negative serum pregnancy test.
             Sexually active females must agree to take appropriate steps not to become pregnant.

          6. Male subjects must agree to use appropriate contraception.

        Exclusion Criteria:

          1. Current clinically significant medical comorbidities, which may substantially
             compromise subject safety, or expose them to undue risk, or interfere significantly
             with study procedures and which, in the opinion of the Investigator, makes the subject
             unsuitable for inclusion in the study.

          2. Body mass index (BMI) <=16.0 kg/m2 or =>40.0 kg/m2.

          3. Current or a history of significant gastrointestinal motility problems

          4. A positive test for hepatitis B surface antigen, hepatitis C antibody or HIV 1 and 2
             antibodies.

          5. A history of substance or alcohol abuse within the last year.

          6. Seizure disorders.

          7. Using phosphate binder medication other than calcium based phosphate binders

          8. Using colestyramine, colestipol or colesevelam

          9. A history of drug or other allergy

         10. Participated in a clinical study with any experimental medication in the last 30 days
             or an experimental biological product within the last 90 days, prior to signing of the
             informed consent.